8 citations
,
February 2010 in “Journal of Dermatology” A topical treatment safely and effectively reduced acne by causing targeted cell death in sebaceous glands without side effects.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules may help treat hair loss by inhibiting 5-alpha reductase.
4 citations
,
January 2023 in “Marine Drugs” Marine compounds from gorgonians and soft corals show promise for drug development, especially for chronic disorders.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
April 2026 in “Future Medicinal Chemistry” PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
January 2021 in “Figshare” Finasteride's molecular properties and active sites were identified using computational methods.
1 citations
,
February 2014 in “Archiv Der Pharmazie” Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
211 citations
,
May 2013 in “Journal of Nutrition Health & Aging” MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.
June 2026 in “Clinical Cosmetic and Investigational Dermatology” High-dose baricitinib improved severe alopecia areata in most patients without severe side effects.
7 citations
,
June 2010 in “Bioorganic & medicinal chemistry letters” Two new compounds were found to effectively reduce hair growth in mice.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
Dutasteride and finasteride can change hair growth genes, helping treat hair loss.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
3 citations
,
September 2023 in “Prostate Cancer and Prostatic Diseases”
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” Inclisiran is effective at lowering cholesterol.
June 2026 in “Eurasian Journal of Medicine” Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.
June 2026 in “Khyber Journal Of Medical Sciences” Tofacitinib works better than methotrexate for severe alopecia in the short term.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
May 2025 in “Reactions Weekly”
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
3 citations
,
April 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” New compounds effective against SARS-CoV-2 variants were identified using a rapid testing method with human lung cells.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
June 2026 in “Drugs & Therapy Perspectives” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.